PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China; Peking University International Hospital, Beijing, China.\', \'Department of Tuberculosis, Wuhan Pulmonary Hospital, Wuhan, 430030, China.\', \'Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China.\', \'Wuhan Jinyintan Hospital, No. 1 Yintan Road, Dongxihu District, Wuhan, 430040, China.\', \'Emergency Department of Peking University International Hospital, Life-Science Park, Changping District, Beijing, 102206, China.\', \'Ezhou Central Hospital, 9 Wenxing Road, Ezhou City, Hubei Province, 463000, China.\', \'Surgical Department, Wuhan Pulmonary Hospital, No. 28 Baofeng Road, Wuhan, 430030, China. Electronic address: 2272534937@qq.com.\', \'Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China; Peking University International Hospital, Beijing, China. Electronic address: john131212@126.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0753-3322(20)31018-010.1016/j.biopha.2020.110825
?:doi
?:hasPublicationType
?:journal
  • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
is ?:pmid of
?:pmid
?:pmid
  • 33378989
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all